B

Bonus Biogroup Ltd
TASE:BONS

Watchlist Manager
Bonus Biogroup Ltd
TASE:BONS
Watchlist
Price: 9.8 ILS 5.38% Market Closed
Market Cap: 119.9m ILS
Have any thoughts about
Bonus Biogroup Ltd?
Write Note

Bonus Biogroup Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Bonus Biogroup Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
B
Bonus Biogroup Ltd
TASE:BONS
Revenue
â‚Ş0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Revenue
$11m
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Revenue
$158.4m
CAGR 3-Years
26%
CAGR 5-Years
2%
CAGR 10-Years
8%
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Revenue
$89.4m
CAGR 3-Years
31%
CAGR 5-Years
437%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Revenue
$99k
CAGR 3-Years
-46%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
No Stocks Found

Bonus Biogroup Ltd
Glance View

Market Cap
119.9m ILS
Industry
Biotechnology

Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. The firm is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. The company is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.

BONS Intrinsic Value
0.41 ILS
Overvaluation 96%
Intrinsic Value
Price
B

See Also

What is Bonus Biogroup Ltd's Revenue?
Revenue
0 ILS

Based on the financial report for Jun 30, 2024, Bonus Biogroup Ltd's Revenue amounts to 0 ILS.

Back to Top